Badanie fazy 1/2 bezpieczeństwa i skuteczności pumitamigu samodzielnie oraz w połączeniu z ipilimumabem i cabozantinibem u pacjentów z zaawansowanym rakiem nerek

In this clinical investigation, patients with Advanced Renal Cell Carcinoma, a late‑stage kidney cancer, are being evaluated. The study examines the investigational medicine pumitamig given by infusion into a vein, either alone or together with the immune‑stimulating drug ipilimumab (administered intravenously) or with the oral medication cabozantinib. The main aim is to determine whether the combination is safe and to see how effectively it can reduce tumor size.

The trial is divided into two parts. In the first part, small groups receive the medicines to monitor side effects and to identify a dose that can be used in later testing. In the second part, larger groups receive the same treatments to assess how many experience a noticeable shrinkage or disappearance of the cancer, as well as how long the disease remains under control. Participants visit the clinic for regular check‑ups, receive the drugs according to the schedule, and undergo imaging tests such as scans to watch the tumor’s response.